A client is undergoing a cytotoxic chemotherapy regimen for the treatment of stage III lung cancer. What effect will this regimen likely have on the client's hemostatic function?
A. The client will require prophylactic heparin.
B. The client will be at increased risk of deep vein thrombosis (DVT).
C. The client will likely experience thrombocytosis.
D. The client's platelet count will decline.